Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar 15:418:63-71.
doi: 10.1016/j.cca.2012.12.026. Epub 2013 Jan 11.

The long and winding road to optimal HbA1c measurement

Randie R Little  1 , Curt L Rohlfing
Affiliations
Review

The long and winding road to optimal HbA1c measurement

Randie R Little et al. Clin Chim Acta. .

Abstract

The importance of hemoglobin A1c (HbA1c) as an indicator of mean glycemia and risks for complications in patients with diabetes mellitus was established by the results of long-term clinical trials, most notably the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS), published in 1993 and 1998 respectively. However, clinical application of recommended HbA1c targets that were based on these studies was difficult due to lack of comparability of HbA1c results among assay methods and laboratories. Thus, the National Glycohemoglobin Standardization Program (NGSP) was initiated in 1996 with the goal of standardizing HbA1c results to those of the DCCT/UKPDS. HbA1c standardization efforts have been highly successful; however, a number of issues have emerged on the "long and winding road" to better HbA1c, including the development of a higher-order HbA1c reference method by the International Federation of Clinical Chemistry (IFCC), recommendations to use HbA1c to diagnose as well as monitor diabetes, and point-of-care (POC) HbA1c testing. Here, we review the past, present and future of HbA1c standardization and describe the current status of HbA1c testing, including limitations that healthcare providers need to be aware of when interpreting HbA1c results.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean HbA1c measured by the CPRL for one very long term QC specimen and six additional QC specimens measured for shorter periods. Each point represents the mean of 34–653 measurements during each year of use. For each point the CV was <3%.
Figure 2
Figure 2
NGSP Network and Process: CPRL, Central Primary Reference Laboratory; PRL, Primary Reference Laboratory; SRL, Secondary Reference Laboratory
Figure 3
Figure 3
Mean of each method compared to the NGSP/DCCT target (dotted lines) in 1993, 1999, 2004, and 2012 based on CAP GH2 survey data. Symbols represent the mean; error bars are ±2SD.
Figure 4
Figure 4
CVs for all HbA1c results on the GH2 CAP surveys between 2000 and 2012 for samples with assigned HbA1c values of (A) 4–6%, (B) 6–8%, and (C) 8–10%. The bold solid line represents the trend line.
See this image and copyright information in PMC

References

    1. World Health Organization. WHO Diabetes Media centre. 2012.
    1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. New Engl J Med. 1993;329:977–986. - PubMed
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–851. - PubMed
    1. Baynes JW, Bunn HF, Goldstein D, et al. National Diabetes Data Group: report of the expert committee on glucosylated hemoglobin. Diabetes Care. 1984;7:602–606. - PubMed
    1. Little RR, Wiedmeyer HM, England JD, Naito HK, Goldstein DE. Interlaboratory comparison of glycohemoglobin results: College of American Pathologists Survey data. Clin Chem. 1991;37:1725–1729. - PubMed

MeSH terms

Substances